Hospitech Respiration Ltd., an Israeli based medical devices company, entered into a new joint venture with Chinese company AwakeZone to be called Hospitech AwakeZone Medical. The venture is for the manufacturing of Hospitech’s AnapnoGuard in China.
AwakeZone Medical will be a new sales and manufacturing subsidiary in China.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
The AnapnoGuard solution provides clinical staff with tools to minimize complications while maintaining the standards of care in intubated and ventilated patients.
It consists of a platform of automated as well as disposable devices.
At a time when American Chinese relations have been strained to say the least amid the entire world has been brought to a standstill because of the Covid-19 Virus, it is refreshing to see Israel make new inroads into joint business ventures with Chinese firms.
This comes at a time when everyone is talking about new Israeli business ties with the two Arab Gulf states of the United Arab Emirates and Bahrain which only just established diplomatic ties with Israel a few short months ago.
“This latest expansion is in response to the increasing demand we are seeing for our advanced airway management devices both in China and globally,” said Yoav Venkert, CEO of Hospitech Respiration.
“We are extremely pleased to announce the establishment of Hospitech AwakeZone Medical Company, a manufacturing and local Chinese sales subsidiary. This joint venture will allow Hospitech to work closely with the local medical professionals and authorities in China, which is becoming the world’s second largest medical device market. We are looking forward to working together to ensure our products become the standard of care in treatment of ventilated patients in the Chinese healthcare system. At the same time, this new joint venture will enable Hospitech Respiration in Israel to focus on further developing its existing advanced solutions while introducing new innovative products in the airway management field,” Mr. Venkert added.
“The systems are in in use in several leading hospital in China since 2018 and were used to treat Covid-19 patients in several hospitals in the Wuhan region,” said Sunny Shan, CEO of AwakZone Medical.
“The Chinese market is offering a great opportunity for Hospitech products with more that 5.5 million beds in total and about 165,000 intensive care beds for ventilated patients in the level II hospital. The establishment of the Hospitech AwakeZone Medical joint venture will provide easier access to the Chinese healthcare system, ensuring Hospitech’s AnapnoGuard device is used in hospitals across China to provide better care and outcome for patients and protection to medical staff.”
